Oct 29, 2026, 11:03 AMEarnings and Guidance
Eli Lilly Raises 2026 Outlook for Third Time as Zepbound Sales Soar
Eli Lilly raised its outlook for a third time in 2026 as Zepbound sales surged and the drug continued to lead the U.S. prescription weight-loss market.
Listen to this briefingAudio briefing
Summary
On October 29, 2026, MarketWatch reported that Eli Lilly raised its outlook for the third time in 2026 as Zepbound sales soared. The prescription weight-loss drug continued to dominate the U.S. market, according to the feed summary.
The limited extracted source did not include the revised outlook, Zepbound sales figures, growth rates, reporting period, or next steps. Those omissions prevent a fuller assessment of Lilly's guidance change and the magnitude of Zepbound's performance.
Positives
- Eli Lilly raised its outlook for the third time in 2026.
- Zepbound sales soared, according to the MarketWatch headline.
- Zepbound continued to dominate the U.S. prescription weight-loss drug market.
Risks & concerns
- The feed omitted Lilly's revised revenue and earnings outlook figures.
- No Zepbound sales amount or growth rate was provided, limiting assessment of the reported surge.
- The limited source disclosed no reporting period, guidance assumptions, or next steps.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/lilly-raises-outlook-for-third-time-this-year-as-zepbound-sales-soar-6d987407?mod=mw_rss_topstories
Read full article
